147 related articles for article (PubMed ID: 16133538)
21. Population pharmacokinetics of carboplatin in children.
Chatelut E; Boddy AV; Peng B; Rubie H; Lavit M; Dezeuze A; Pearson AD; Roché H; Robert A; Newell DR; Canal P
Clin Pharmacol Ther; 1996 Apr; 59(4):436-43. PubMed ID: 8612389
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin dosing: gender bias and inaccurate estimates of glomerular filtration rate.
Dooley MJ; Poole SG; Rischin D; Webster LK
Eur J Cancer; 2002 Jan; 38(1):44-51. PubMed ID: 11750838
[TBL] [Abstract][Full Text] [Related]
23. Dose-banding of carboplatin: rationale and proposed banding scheme.
Kaestner S; Sewell G
J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
[TBL] [Abstract][Full Text] [Related]
24. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
[TBL] [Abstract][Full Text] [Related]
25. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
[TBL] [Abstract][Full Text] [Related]
26. Dose individualization can minimize nephrotoxicity due to carboplatin therapy in patients with ovarian cancer.
Donadio C; Lucchesi A; Ardini M; Cosio S; Fanucchi A; Gadducci A
Ther Drug Monit; 2009 Feb; 31(1):63-9. PubMed ID: 19077927
[TBL] [Abstract][Full Text] [Related]
27. A modified Cockcroft-Gault formula taking into account the body surface area gives a more accurate estimation of the glomerular filtration rate.
Rostoker G; Andrivet P; Pham I; Griuncelli M; Adnot S
J Nephrol; 2007; 20(5):576-85. PubMed ID: 17918143
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of two dose individualisation methods for carboplatin.
Desoize B; Dufour R; Urien S; Kaltenbach M; Colin P
Anticancer Res; 1996; 16(4A):2073-8. PubMed ID: 8712745
[TBL] [Abstract][Full Text] [Related]
29. [Estimating renal function based on creatinine clearance: application of different formulas and correction for obese patients].
Apperloo JJ; Gerlag PG; Beerenhout CH; Vader HL
Ned Tijdschr Geneeskd; 2007 May; 151(18):1016-23. PubMed ID: 17508688
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma.
Niioka T; Uno T; Yasui-Furukori N; Takahata T; Shimizu M; Sugawara K; Tateishi T
Cancer Chemother Pharmacol; 2007 Apr; 59(5):575-80. PubMed ID: 16912889
[TBL] [Abstract][Full Text] [Related]
31. Comparison of estimated glomerular filtration rate with estimated creatinine clearance in the dosing of drugs requiring adjustments in elderly patients with declining renal function.
Spruill WJ; Wade WE; Cobb HH
Am J Geriatr Pharmacother; 2008 Aug; 6(3):153-60. PubMed ID: 18775390
[TBL] [Abstract][Full Text] [Related]
32. Modification of Diet in Renal Disease and modified Cockcroft-Gault formulas in predicting aminoglycoside elimination.
Bookstaver PB; Johnson JW; McCoy TP; Stewart D; Williamson JC
Ann Pharmacother; 2008 Dec; 42(12):1758-65. PubMed ID: 19047358
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
[TBL] [Abstract][Full Text] [Related]
34. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
[TBL] [Abstract][Full Text] [Related]
35. [Serum creatinine and creatinine clearance to estimate renal function in essential hypertension].
Jabary NS; Martín D; Muñoz MF; Santos M; Herruzo J; Gordillo R; Bustamante J
Nefrologia; 2006; 26(1):64-73. PubMed ID: 16649427
[TBL] [Abstract][Full Text] [Related]
36. Carboplatin dosing based on measurement of renal function--experience at the Peter MacCallum Cancer Institute.
Millward MJ; Webster LK; Toner GC; Bishop JF; Rischin D; Stokes KH; Johnston VK; Hicks R
Aust N Z J Med; 1996 Jun; 26(3):372-9. PubMed ID: 8811211
[TBL] [Abstract][Full Text] [Related]
37. Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Nannan Panday VR; van Warmerdam LJ; Huizing MT; Ten Bokkel Huinink WW; Vermorken JB; Giaccone G; Veenhof CH; Schellens JH; Beijnen JH
Clin Drug Investig; 1998; 15(4):327-35. PubMed ID: 18370488
[TBL] [Abstract][Full Text] [Related]
38. [Dose individualization for carboplatin in cancer chemotherapy].
Oudard S; Lauraine EP
Bull Cancer; 1997 Jun; 84(6):675-7. PubMed ID: 9295872
[TBL] [Abstract][Full Text] [Related]
39. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
40. Creatinine-clearance estimates for predicting gentamicin pharmacokinetic values in obese patients.
Leader WG; Tsubaki T; Chandler MH
Am J Hosp Pharm; 1994 Sep; 51(17):2125-30. PubMed ID: 7985687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
